Verona Pharma, which is developing inhaled treatments for respiratory diseases, filed on Monday with the SEC to raise up to $86 million in a US initial public offering. Verona currently trades on London's AIM under the symbol VRP.
The London, United Kingdom-based company was founded in 2005 and plans to list on the Nasdaq under the symbol VRNA. Verona Pharma filed confidentially on November 23, 2016. Jefferies and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.
